UNICYCIVE THERAPEUTICS INC
UNCYNASDAQTrading Snapshot
- Day Range
- $4.51 – $4.61
- 52-Week Range
- $3.93 – $8.74
- Volume
- $4.34B
- Avg Volume
- $3.57B
- Shares Outstanding
- 26.7M
- Next Earnings
- Oct 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $22M
- Last Q Revenue
- $5M
- P/E Ratio
- -2.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.31
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +155.2%
Why Investors Own UNCY
- ✓High-growth profile — revenue up +4.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 37% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
UNICYCIVE THERAPEUTICS INC
UNCY
StockOtter · stockotter.spaceAbout UNICYCIVE THERAPEUTICS INC
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
New York, New York--(Newsfile Corp. - September 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 202
Kaplan Fox Notifies Investors of Unicycive Therapeutics, Inc. (UNCY) of the Lead Plaintiff Deadline on November 2, 2026
New York, New York--(Newsfile Corp. - September 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UN
UNCY LAWSUIT: Unicycive Therapeutics Investors Should Contact Block & Leviton to Possibly Recover Losses
Boston, Massachusetts--(Newsfile Corp. - September 29, 2026) - Block & Leviton reminds investors that a securities fraud lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its execu
Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming November 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investo
SueWallSt Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY
A securities class action alleges Unicycive Therapeutics resubmitted its oxylanthanum carbonate New Drug Application without ever inspecting its third-party manufacturer's facility for cGMP compliance. Pension funds, ass
UNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Uni